Kalfoglou Andrea L
Associate professor in the Department of Sociology and Anthropology at the University of Maryland Baltimore County in Baltimore.
AMA J Ethics. 2016 Jun 1;18(6):614-23. doi: 10.1001/journalofethics.2016.18.6.stas1-1606.
Approximately 15 percent of women experience depression while pregnant or in the year following pregnancy. While antidepressants are usually effective and considered standard treatment for depression, concerns arise that what might be good for mom could be harmful for the baby. Medical evidence demonstrates that, on balance, treating mental illness with psychotropic medication along with talk therapy is in the best interest of both mother and baby; however, women may resist treatment because they overestimate the risks of medication and underestimate the risks of untreated mental illness. Clinicians can help address this perceived ethical dilemma and provide optimum care to their pregnant patients by collaborating with their patients on a treatment plan, informing them about the risks of untreated mental illness, and providing reassurance that selective serotonin reuptake inhibitors (SSRIs) and many other psychotropic medications are appropriate care even if a woman is pregnant or breastfeeding.
约15%的女性在孕期或产后一年内会出现抑郁症状。虽然抗抑郁药通常有效且被视为抑郁症的标准治疗方法，但人们担心对母亲有益的药物可能对婴儿有害。医学证据表明，总体而言，使用精神药物结合心理治疗来治疗精神疾病对母婴双方都是最有利的；然而，女性可能会拒绝治疗，因为她们高估了药物的风险，而低估了未治疗的精神疾病的风险。临床医生可以通过与患者共同制定治疗计划、告知她们未治疗的精神疾病的风险，并让她们放心即使女性怀孕或正在哺乳，选择性5-羟色胺再摄取抑制剂（SSRI）和许多其他精神药物也是合适的治疗方法，来帮助解决这种被认为的伦理困境，并为她们的怀孕患者提供最佳护理。
